DE-RISK CLINICAL TRIALS WITH MORE RELEVANT PRECLINICAL O-PDX MOUSE MODELS

The most robust, efficient and effective models are orthotopic patient-derived xenograft (PDX) models.¹Widely viewed as the "gold standard" of xenograft tumor models in oncology research, Certis brings a whole new level of excellence to PDX model development and in vitro and in vivo study design and execution.

Better in vivo data begins with better PDX models

When seeking clear and compelling evidence of anticancer drug efficacy, the most clinically relevant research in vivo model available is an orthotopic patient-derived xenograft (orthotopic PDX or O-PDX murine models).

Custom Model Development

For early-stage in vivo testing programs, talk to us about custom subcutaneous PDX or Cell line-derived xenograft (CDX) models. Need to start screening with the best possible in vitro model? Let’s discuss custom cell lines derived from our PDX mouse models to ensure.

Expert Study Design

Our scientific team provides expert input into tolerability and efficacy study designs with flexible options for dosing, frequency of formulation and imaging, in-life bleeds and measure-only extensions

Advanced Imaging

With high-resolution imaging technology, our cancer researchers not only overcome variability associated with manual tumor volume measurement (TVM), we are able to study tumor response in real time—quantitatively, repeatedly, without interfering with the microenvironment or biological processes under study. Industry-leading imaging technologies, including our own murine-scale MRI machine, enable precise measurement of tumor volume without resection—and offers visual reproducible proof of tumor response beyond graphs.

in vivo studies

Clinically Relevant Orthotopic Patient-Derived Xenograft Tumor Models

Certis custom-develops the world’s most clinically relevant, orthotopic patient-derived xenograft (O-PDX) tumor models to study individual cancers and their response to therapies.

Icon_pharmacology-study Poor efficacy results account for 57% of late-stage failures in oncology clinical trials²

O-PDX tumor models preserve the histological architecture, stroma construction, and gene-expression or mutation status of original human tumor tissue.³
O-PDX models replicate the human tumor microenvironment, which is critical to cancer progression and metastasis.⁴
O-PDX models can predict acquired drug resistance and multiple drug resistance (MDR)— before these events are observed in donor patients.⁵

The Result: Clinically relevant results, and reliable, actionable information for your go or no-go development decisions.

Our Team of Precision Experts

Our culture fosters collaboration, precision and exacting scientific standards. Collaborate with our specialized team of PhD scientists with deep knowledge of orthotopic PDX development, advanced imaging technologies and bioassay expertise. From study design through execution, you’ll work closely with our experts.

in vivo Assays Paired with advanced imaging

We pair orthotopic tumor models with advanced diagnostic technologies and relentless scientific resolve to predict therapeutic response with certainty. We use murine-scale imaging technology to visually confirm changes in tumor volume.

The Result: Armed with this information, you can make development decisions with certainty—more confident that results from animal studies will translate into clinical development.

EX vivo and in vitro screening

To support early screening studies, Certis also offers proprietary cell lines derived from our PDX tumor models, providing a paired platform for transitioning from in vitro to in vivo studies. Our integrated approach empowers you to make decisions that are more precise, timely and cost-efficient.

Copy Number Variation
Fusions
Expression Level
Histology
MRI

For many specimens, the donor patient’s full treatment history is available. If your desired phenotype is particularly difficult to find, Certis has the necessary CLIA license to directly source tissue. Both in vitro and in vivo test systems can be customized to mimic immune response, using humanized mouse models.

Our collaborations with a number of hospital systems, cancer centers and private practices facilitate access to a broad array of tumor tissues and malignancies.